

Development of lead compounds as antidepressant having both α_2 adrenergic antagonist and NDRI activities

Kyung Hee University



NEUROSCIENCE	Hit
Product Type	Chemical Product
Indication	1st indication : Depression 2nd indication : ADHD, Autism
Target	α_2 adrenergic antagonist and NDRI
MoA(Mechanism of Action)	NDR inhibition + α_2 adrenergic receptor antagonist → Increases NE and DA at nerve terminal through NDRR and α_2 adrenergic receptor antagonism
Competitiveness	<ul style="list-style-type: none"> • Development of a new class of antidepressants that increase NE and DA in the nerve terminals through NDRI and α_2 adrenergic receptor antagonism • Lead compound without any adverse effects observed in conventional drug, such as sexual dysfunction, cognitive impairments
Development Stage	Hit
Route of Administration	Parenteral-intraperitoneal